Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count.
Guillaume GermainKaren WorleySean D MacKnightBernard RubinChristopher F BellFrançois LalibertéAna UrosevicMei Sheng DuhAndrew ConcoffPublished in: Lupus science & medicine (2024)
In this real-world effectiveness study, belimumab therapy for SLE resulted in clinically meaningful improvements in rheumatoid arthritis-derived disease activity measures within 3 months of treatment, with patients who remained on belimumab therapy experiencing improvement even up to 24 months of observation.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- rheumatoid arthritis
- randomized controlled trial
- juvenile idiopathic arthritis
- systematic review
- replacement therapy
- systemic sclerosis
- mesenchymal stem cells
- combination therapy
- smoking cessation
- idiopathic pulmonary fibrosis